We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Incyte shares (NASDAQ:INCY) saw their price target increased by TD Cowen from $86.00 to $88.00, with the firm maintaining a ...

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...

Earnings per Share (EPS) is expected to be $1.58, indicating a 49.1% increase year-over-year. Projected revenue is at $1.15 ...

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.

Jakafi is approved for use in patients with two types of cancers, myelofibrosis and polycythemia vera. Incyte forecast Jakafi sales in 2025 to be between $2.93 billion and $2.98 billion. Sales of ...

A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes ...